Colgate-Palmolive Company

🇺🇸New York Stock Exchange
Back to all articles
Colgate-Palmolive Company stock analysis CL overview
Somewhat Bullish +35

Top Stock Picks of 2026: Colgate-Palmolive

📊 Colgate-Palmolive is identified as one of Schaeffer's top 15 stock picks for 2026, highlighted in a quarterly analysis published on December 23.

📉 The stock trades near the lower boundary of a long-term bullish trend channel and its 128-month moving average, which has supported lows since October 2004.

🛡️ Strong support is established at the $75 price level, marking a 38.2% Fibonacci retracement from previous highs that historically triggered rebounds.

💰 Technical indicators show peak put open interest at $75 and an unwinding of negativity, with call/put volume ratios signaling bullish sentiment across major exchanges.

📉 Short interest is approaching all-time highs with 14.30 million shares sold short, while the majority of analysts maintain hold or worse ratings.

💸 Analyst price targets remain mixed, ranging from $86 trimmings by Piper Sandler and TD Cowen to $105 lifts by BofA and Goldman Sachs.

📈 Major financial institutions including Wells Fargo, JPMorgan, Citi, and Morgan Stanley have refreshed or raised targets in early 2026 to reflect broad interest in the company's 2030 plan.

💡 Key drivers for growth include Colgate Palmolive’s SGPP program, product pipeline expansion, emerging markets exposure, and reduced drag from its pet food exit.

📈 Management provided earnings guidance for 2026 projecting net sales growth between 2% to 6%, with organic sales growth expected at 1% to 4%.

💰 The company anticipates gross profit margin expansion on a GAAP basis alongside double-digit earnings per share growth driven by increased advertising spend.

🔄 A share buyback program announced in March 2025 has seen the company repurchase over 5.8 million shares for approximately $516 million, with no further activity since October.

📈 The modeled fair value was nudged higher from $96.68 to roughly $97.21, reflecting adjustments in revenue growth expectations and net profit margins.

⚠️ Identified risks include consumer caution in key markets like North America, Brazil, and India, along with higher raw material and packaging costs.

🤖 Strategic initiatives focus on AI, digital transformation, and productivity programs including up to $300 million in restructuring costs over three years.

Bullish Signals
  • Colgate-Palmolive is trading near the lower rail of a long-term bullish trend channel and has strong support at $75, with historical rebound patterns from this level. Multiple major banks including BofA and Goldman Sachs lifted their price targets to $105 and $100 respectively, citing confidence in the company's 2030 plan and product pipeline. Analyst consensus shows early signs of improvement in emerging markets and reduced reliance on a stretched US market, making current valuation attractive with potential upside. Management expects earnings per share growth in double digits for 2026 alongside gross profit margin expansion and net sales growth of 2% to 6%. The company successfully completed the buyback of 5.89 million shares worth $515.76 million under its share repurchase program announced on March 20, 2025. Product strategy focuses on expansion and premiumization in core oral care with AI and digital transformation initiatives intended to free up resources for growth. The company's restructuring plans include $200m to $300m over three years aimed at improving productivity and supporting long-term execution of its 2030 plan. Analysts from multiple houses including Wells Fargo, JPMorgan, Citi, Morgan Stanley, TD Cowen, Barclays and UBS have refreshed or raised targets through early 2026.
Risk Factors
  • Wells Fargo has an Equal Weight rating at a US$100 target, with earlier moves to Underweight at US$86 reflecting concern over recent risks to sales growth and valuation.
  • TD Cowen downgraded the target to US$86 in January, citing a challenging setup for large cap staples due to limited volume improvement and muted pricing power.
  • The company expects net sales growth of only 2% to 6% for 2026, with minimal positive impact from foreign exchange included in that range.
  • Organic sales growth guidance is narrow at 1% to 4% for 2026, partly due to the approximately 20 basis point drag from exiting the private label pet food business.
  • Key risks include consumer caution in major markets like North America, Brazil, and India, which could dampen volume recovery.
  • Rising costs in raw materials and packaging threaten to compress profit margins despite the company's cost-cutting initiatives.
  • Competition is intensifying in key categories such as pet food and local brands, putting pressure on market share and pricing power.
Full Analysis
Schaeffer's has identified Colgate-Palmolive (NYSE:CL) as one of its top 15 stock picks for 2026, citing technical indicators that suggest a bullish trend channel with strong support near the $75 level. This price point coincides with significant put open interest and a 38.2% Fibonacci retracement of historical lows from 2000 to September 2024 highs, a level from which the stock historically rebounds. Market sentiment appears mixed, with 14.30 million shares sold short nearing all-time highs while ten of the 21 analysts covering the stock maintain hold or worse ratings; however, options data indicates optimism with a put/call open interest ratio of 2.03 and high volume ratios for calls across major exchanges like the CBOE and ISE. Analyst price targets for Colgate-Palmolive remain dispersed, ranging from US$86 to US$105, reflecting varying assessments of the company's 2030 strategic plan against sector headwinds. Major banks like Bank of America and Goldman Sachs raised their targets to US$105 and US$100 respectively, driven by confidence in the product pipeline and emerging market exposure, while Piper Sandler upgraded its rating with a US$88 target despite acknowledging valuation pressures. Conversely, houses like TD Cowen lowered targets to US$86 due to challenging large-cap staple conditions, and Wells Fargo maintains an Equal Weight at US$100 but notes risks to sales growth are already priced in. For 2026, Colgate-Palmolive issued earnings guidance projecting net sales growth between 2% and 6%, with organic sales expected to grow 1% to 4% before excluding the approximately 20 basis point impact from exiting its private label pet food business. Management anticipates double-digit earnings per share growth alongside gross profit margin expansion, supported by higher advertising spend and restructuring programs involving US$200m to US$300m over three years aimed at AI-driven digital transformation. However, the company faces specific risks including consumer caution in key markets such as North America, Brazil, and India, along with elevated raw material costs and intensified competition in categories like pet food and local bran.